ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0453

Effects of Roxadustat in Patients with Dialysis-Dependent CKD (DD-CKD) Across All Baseline (BL) Hemoglobin (Hb) Values

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Bhandari, Sunil, Hull University Teaching Hospitals NHS Trust, Hull, Kingston upon Hull, United Kingdom
  • Pollock, Carol A., The University of Sydney, Sydney, New South Wales, Australia
  • Tham, Stefan, Clinical Research, AstraZeneca, Gothenburg, Sweden
  • Rastogi, Anjay, University of California Los Angeles, Los Angeles, California, United States
Background

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, increases Hb by stimulating endogenous erythropoietin synthesis and improving iron bioavailability. This pooled post hoc analysis evaluated the efficacy and safety of roxadustat in patients (pts) with DD-CKD across all available BL Hb values.

Methods

Pts were randomized to open-label roxadustat (n=1943) or epoetin alfa (EPO; n=1947) in 3 Phase 3 DD-CKD trials (ROCKIES, SIERRAS, HIMALAYAS). Across trials, Hb eligibility criteria were <10 or 8.5–12 g/dL at final screening. EPO and intravenous (IV) iron were given per local care for the EPO group; for roxadustat, dose was titrated to Hb 11±1 g/dL and IV iron limited to need. Pooled subgroup analyses were performed by selected Hb values (g/dL: <8.0, ≥8.0–<9.0, ≥9.0–<10, ≥10.0) at BL (mean of up to 4 pre-randomization values) regardless of study rescue therapy use. Adverse events (AEs) were assessed.

Results

Pt study discontinuation rates were similar across BL Hb ranges (Table). Pts with lower BL Hb had less time on dialysis (Table), suggesting pts incident to dialysis. At BL, pts with Hb <9 g/dL had the lowest weekly ESA doses, but by Weeks (wk) 49–52 their weekly ESA doses were highest (Table). Pts with BL Hb <8 g/dL received on average ~1 mg/kg/wk more roxadustat dose at wk 49–52 than pts with BL Hb ≥10 g/dL (Table). Rates of serious AEs (SAEs) and treatment-emergent SAEs per pt-exposure year were comparable for roxadustat vs EPO and appeared more common in pts with higher BL Hb (Table).

Conclusion

DD-CKD pts with more severe anemia at BL required more IV iron during the study. Roxadustat was effective and had comparable tolerability to EPO across all BL Hb studied.

Funding

  • Commercial Support